Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:CLDXNASDAQ:FOLDNASDAQ:IONS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.09-0.8%$29.81$22.90▼$36.45$4.80B0.471.73 million shs3.63 million shsCLDXCelldex Therapeutics$20.50-1.5%$19.87$14.40▼$47.00$1.36B1.33941,890 shs1.56 million shsFOLDAmicus Therapeutics$5.64-1.6%$6.39$5.62▼$12.65$1.74B0.543.08 million shs17.42 million shsIONSIonis Pharmaceuticals$37.41+1.1%$32.88$23.95▼$52.34$5.95B0.181.60 million shs2.29 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-2.48%-0.89%-16.38%+16.59%CLDXCelldex Therapeutics0.00%-3.57%+0.74%-1.35%-41.88%FOLDAmicus Therapeutics0.00%-6.47%-9.32%-35.10%-44.10%IONSIonis Pharmaceuticals0.00%+5.11%+13.43%+11.84%-10.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.756 of 5 stars4.41.00.04.23.32.51.9CLDXCelldex Therapeutics2.7593 of 5 stars4.43.00.00.02.80.00.0FOLDAmicus Therapeutics3.9636 of 5 stars3.42.00.04.31.80.01.9IONSIonis Pharmaceuticals4.4716 of 5 stars4.32.00.03.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0037.50% UpsideCLDXCelldex Therapeutics 2.89Moderate Buy$50.11144.44% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22187.63% UpsideIONSIonis Pharmaceuticals 2.68Moderate Buy$57.5953.94% UpsideCurrent Analyst Ratings BreakdownLatest CLDX, IONS, ALKS, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.08$2.65 per share10.97$9.05 per share3.21CLDXCelldex Therapeutics$7.02M193.84N/AN/A$11.26 per share1.82FOLDAmicus Therapeutics$528.29M3.29N/AN/A$0.65 per share8.68IONSIonis Pharmaceuticals$705M8.45N/AN/A$3.73 per share10.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.9221.231.8023.30%27.52%17.98%7/23/2025 (Estimated)CLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A13.12N/A-5.41%4.67%1.05%8/14/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)Latest CLDX, IONS, ALKS, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92CLDXCelldex TherapeuticsN/A21.6721.67FOLDAmicus Therapeutics2.023.342.47IONSIonis Pharmaceuticals2.639.669.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/AIONSIonis Pharmaceuticals93.86%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%CLDXCelldex Therapeutics4.40%FOLDAmicus Therapeutics2.20%IONSIonis Pharmaceuticals2.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million154.85 millionOptionableCLDX, IONS, ALKS, and FOLD HeadlinesRecent News About These CompaniesIonis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to RetireJune 20 at 10:37 AM | msn.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by GAMMA Investing LLCJune 17, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $48.00June 14, 2025 | americanbankingnews.comIonis Treats First Patient in Phase III Antisense Oligonucleotide Trial in Angelman SyndromeJune 12, 2025 | precisionmedicineonline.comIonis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026June 12, 2025 | finance.yahoo.com5IONS : Analyst Expectations For Ionis Pharmaceuticals's FutureJune 12, 2025 | benzinga.comJPMorgan Chase & Co. Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $48.00June 12, 2025 | marketbeat.comFirst patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndromeJune 11, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 7, 2025 | marketbeat.comCalifornia State Teachers Retirement System Acquires 7,722 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)June 3, 2025 | marketbeat.comWhy Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?May 30, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $21.66 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 29, 2025 | marketbeat.comNuveen Asset Management LLC Trims Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 29, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 63,698 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 27, 2025 | marketbeat.comWoodline Partners LP Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 27, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 26, 2025 | marketbeat.comDecember 2027 Options Now Available For Ionis Pharmaceuticals (IONS)May 25, 2025 | nasdaq.comIonis’ olezarsen shows new promise with strong Phase III resultsMay 23, 2025 | thepharmaletter.comIonis Builds Triglyceride-Lowering Case for RNA-Targeting TryngolzaMay 20, 2025 | biospace.com6IONS : Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14...May 20, 2025 | benzinga.comIonis' Tryngolza Cuts Triglyceride Levels in Late-Stage StudyMay 20, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next RallyArcher Aviation Stock Steadies After Short-Seller ReportBy Jeffrey Neal Johnson | May 30, 2025View Archer Aviation Stock Steadies After Short-Seller Report3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to BuyCLDX, IONS, ALKS, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$29.09 -0.24 (-0.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$28.66 -0.43 (-1.48%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Celldex Therapeutics NASDAQ:CLDX$20.50 -0.32 (-1.54%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$19.93 -0.57 (-2.78%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$5.64 -0.09 (-1.57%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.64 +0.00 (+0.09%) As of 06/20/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ionis Pharmaceuticals NASDAQ:IONS$37.41 +0.40 (+1.08%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$37.76 +0.36 (+0.95%) As of 06/20/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
